[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sarcopenic-obesity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sarcopenic-obesity":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,41,75,101,135,157,177,223,250,274,310,335,361,387,411,434],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100637753","effect-of-combined-resisted-training-and-protein-based-diet-on-frailty-in-sarcopenic-elderly-women-100637753",false,"NCT07627919","Effect of Combined Resisted Training and Protein-based Diet on Frailty in Sarcopenic Elderly Women","Inclusion Criteria:\n\n* 1\\) Female gender 2) Age 60-70 years 3) BMI ≥ 30 kg\u002Fm2 4) Sarcopenic patients diagnosed by their physicians according to EWGSOP2 criteria (low muscle strength confirmed by handgrip strength or chair stand test, plus low muscle quantity confirmed by BIA or DXA), and SARC-F score \\>3.\n\n  5\\) Ambulatory and able to participate in exercise. 6) Stable medical condition. 7) The patients didn't follow any type of diet before the treatment at least 4 weeks ago.\n\n  8\\) Patients didn't follow any exercise program before treatment at least 4 weeks ago.\n\nExclusion Criteria:\n\n* 1\\) Sever cardiovascular, pulmonary, renal, or hepatic disease. 2) Uncontrolled diabetes or hypertension. 3) Neurological or musculoskeletal disorders prohibiting exercise 4) Cancer or other terminal illness. 5) Current use of anti-inflammatory drugs or steroids. 6) Metal implants prohibiting BIA assessment. 7) Cognitive impairment impairing ability to consent or follow instructions. 8) Using drugs that would affect metabolism or balance. 9) Using assistive devices for walking.","FEMALE","60 Years","70 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","Sixty obese elderly women will be recruited from Fawkia hospital outpatient clinic diagnosed by sarcopenia and randomly allocated into two groups for a 12-week intervention. Patients will be divided into 2 groups (A and B):\n\n* Group A (combined intervention group: n=30): will perform supervised resistance exercise training three times per week and follow a high-protein diet (1.3 g protein\u002Fkg\u002Fday)\n* Group B (control group: n=30): will receive a high-protein diet and general health advices and be asked to maintain their usual lifestyle. They will be offered the intervention post-study.",[26,27],"Obese","Sarcopenic Obesity","RECRUITING","2026-05-30",{"date":31,"type":32},"2026-06-04","ACTUAL",{"date":34,"type":20},"2026-06-30",{"date":36,"type":20},"2027-12-30",{"name":38,"class":39},"Cairo University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":40},"100604838","phase-4-glp-1r-actions-on-muscle-and-the-skeleton-100604838","NCT07154719","GLP-1R Actions on Muscle and the Skeleton","GRAMS","Inclusion Criteria:\n\n* Subjects will have a BMI between 30kg\u002Fm2\n\n  * 40kg\u002Fm2 (inclusive)\n* Be between 18 and 50 years of age (inclusive).\n* Non-Hispanic Black males and females will be enrolled at PBRC.\n* Rural males and females will be enrolled at MaineHealth.\n* Female subjects will be premenopausal.\n* Females have had their last menstrual period less than 60 days before screening.\n* Females have the absence of menopausal-associated vasomotor symptoms.\n* All subjects must be able to use Lifestyle Toolkit as prescribed for intervention arm.\n\nExclusion Criteria:\n\n\\- Males and females over the age of 50 years of age\n\n* Menopausal females.\n* Subjects on systemic corticosteroids or other agents known to increase loss of muscle and bone mass.\n* Subjects who are on medications that increase or decrease weight status.\n* Subjects having contraindications to tirzepatide in the package insert.\n* Subjects with a history of malignancy other than non-melanoma skin cancer\n* Subjects with known osteoporosis or are on osteoporosis therapies (gonadal hormones or hormone antagonists).\n* Subjects with uncontrolled thyroid or parathyroid disease that may influence the study results.\n* Subjects with a clinically significant hematologic abnormality, kidney disease, liver disease, or diabetes.\n* Females of childbearing potential who do not agree to using an effective method of contraception during the study. Medically acceptable methods include oral contraceptive medication, an intrauterine device (IUD), an implantable contraceptive (such as Implanon), or a barrier method (such as condom or diaphragm with spermicide).\n\nInjectable contraceptives such as Depo-Provera are a cause for exclusion in that they can cause bone loss.\n\nAbstinence is acceptable, as is sexual activity exclusively with same sex partners.\n\nFertility Appreciation Based Methods (natural family planning) are also acceptable forms of addressing childbearing potential in all subjects. A urine pregnancy test (UPT) will be performed on all females of childbearing potential at the screening visit, 3 and 6 months.\n\n* Unable to follow Lifestyle Toolkit as prescribed for intervention arm.\n* Patient Health Questionnaire-9 (PHQ-9) Score equal to or greater than 15 (clinical depression).\n* Adults who are unable to consent.\n* Individuals who are not yet adults (infants, children and teenagers).\n* Pregnant females.\n* Incarcerated individuals.\n* Contraindication to MRI - including but not limited to non-removable metallic or electronic implants, claustrophobia or other fear of confinement, inability to tolerate loud scanner noise, body weight greater than 500 pounds.\n* Subjects with a baseline level of 25-OH vitamin D \\\u003C15 ng\u002Fml will be excluded from the trial. The subject's physician will be notified, and the subject will be referred to their primary care physician.\n* Any significant EKG abnormalities that are considered a risk for utilizing weight management therapies.","ALL","18 Years","50 Years",{"count":52,"type":20},50,[54],"PHASE4","The GRAMS study objectives are to assess the musculoskeletal changes that occur after weight loss using GLP-1 based therapy. A lifestyle intervention with diet and exercise is included to assess any mitigating effects are provided, versus a control group with regular exercise and diet.",[57,58,27,59,60],"Musculoskeletal Abnormalities","Obesity","Osteoporosis","Drug Effect",[62,63,64,65],"GLP-1 agonists","Obesity treatments","Muscleskeletal loss","Tirzepatide","2026-05-26",{"date":68,"type":32},"2026-05-29",{"date":70,"type":32},"2025-10-09",{"date":72,"type":20},"2027-05-01",{"name":74,"class":39},"Pennington Biomedical Research Center",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":48,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":40},"100639577","effects-of-obesity-on-physical-abilities-and-daily-living-activities-in-elderly-adults-100639577","NCT07614464","Effects of Obesity on Physical Abilities and Daily Living Activities in Elderly Adults","CAPFISOBEANZ","Obese elderly:\n\nInclusion Criteria:\n\n* Both sexes\n* Body Mass Index \\> 35 kg\u002Fm2\n* Age \\> 65 years\n* Hospitalized for a 3-week integrated metabolic rehabilitation program\n\nExclusion Criteria:\n\n* Absence of signed informed consent\n\nNormal weight elderly:\n\nInclusion Criteria:\n\n* Both sexes\n* Body Mass Index 20-25 kg\u002Fm2\n* Age \\> 65 years\n* Attendance of healthy lifestyle program in their home town\n\nExclusion Criteria:\n\n* Absence of signed informed consent",true,"65 Years",{"count":85,"type":20},160,"OBSERVATIONAL","Obesity is a significant health problem whose prevalence has tripled worldwide in the last fifty years, also involving older people. Older people present sarcopenia, characterized by the progressive loss of muscle mass and strength. Sarcopenia, accompanied by an increase in adipose tissue, causes a specific condition called sarcopenic obesity. The increase in adipose tissue and the decrease in muscle mass determines a reduction in strength and physical abilities necessary to perform everyday activities of daily living in obese older people.\n\nTo understand how the condition of excess adipose tissue influences the activities of daily living of older people with obesity, it is necessary to compare the physical abilities, body composition, and results of various motor skills with normal-weight subjects, corrected for sex and age.",[58,27],[90,58,91,92],"Ageing","Physical performance","Visceral adiposity","2026-05-22",{"date":68,"type":32},{"date":96,"type":32},"2025-05-29",{"date":98,"type":20},"2026-12-31",{"name":100,"class":39},"Istituto Auxologico Italiano",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":48,"minAge":49,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":111,"conditions":112,"keywords":116,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":4},"100626259","ct-body-composition-as-predictor-of-exercise-therapy-outcome-in-peripheral-arterial-disease-100626259","NCT07433309","CT Body Composition as Predictor of Exercise Therapy Outcome in Peripheral Arterial Disease","CT Body Composition Predicts Supervised Exercise Response in Peripheral Arterial Disease: A Protocol","COMPOSE-PAD","Inclusion Criteria:\n\n* Age 18 years or older\n* Confirmed peripheral arterial disease (PAD) defined by at least one of: resting ankle-brachial index (ABI) ≤0.90, duplex ultrasonography demonstrating ≥50% stenosis in a relevant lower extremity vessel, or CT angiography (CTA) or magnetic resonance angiography (MRA) demonstrating flow-limiting lower extremity arterial disease\n* Fontaine stage IIa or IIb intermittent claudication\n* Scheduled for the institutional 36-session supervised exercise therapy (SET) programme\n* Existing CTA with an axial slice at the L3 vertebral level suitable for automated body composition analysis\n* Capacity to provide written informed consent\n\nExclusion Criteria:\n\n* Fontaine stage III or IV peripheral arterial disease (rest pain or tissue loss; critical limb-threatening ischaemia)\n* Ipsilateral lower extremity revascularisation within 6 months prior to enrolment\n* Absolute contraindication to structured exercise (e.g., unstable coronary artery disease, severe pulmonary hypertension, uncontrolled arrhythmia, or other condition precluding participation in a supervised treadmill and resistance exercise programme)\n* Cognitive impairment (Mini-Mental State Examination \\[MMSE\\] score \\\u003C24)\n* Active malignancy or systemic condition expected to substantially alter body composition independently of the exercise intervention during the study period\n* Estimated life expectancy less than 12 months",{"count":110,"type":20},128,"Supervised exercise therapy (SET) is the recommended first treatment for patients with leg artery disease (peripheral arterial disease, PAD) causing pain when walking. However, approximately 40% of patients do not benefit meaningfully and go on to require a procedure to open the blocked arteries within three months. This study investigates whether body composition measurements - specifically the quality of muscle and the amount of belly fat - taken from a CT scan already performed as part of routine care, can identify before treatment begins which patients are unlikely to respond to exercise therapy. If confirmed, this approach would allow doctors to use information from a scan patients are already having, with no additional tests, to better match patients to the right treatment from the start.",[113,114,27,115],"Sarcopenia","Body Composition","Peripheral Arterial Disease",[117,118,119,120,121,122,123,124],"Peripheral arterial disease","intermittent claudication","supervised exercise therapy","computed tomography body composition","myosteatosis","visceral adipose tissue","sarcopenic obesity","treatment outcome prediction","NOT_YET_RECRUITING","2026-02-20",{"date":128,"type":32},"2026-02-25",{"date":130,"type":20},"2026-06-01",{"date":132,"type":20},"2031-01-31",{"name":134,"class":39},"Nemocnice AGEL Trinec-Podlesi a.s.",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":48,"minAge":49,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":21,"phases":143,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":40},"100475926","adverse-outcomes-and-mortality-in-liver-transplant-100475926","NCT05477277","Adverse Outcomes and Mortality in Liver Transplant","Inclusion Criteria:\n\n1. All patients with end-stage liver disease undergoing evaluation for liver transplantation\n2. Patient clinically indicated for MRI during transplant candidacy evaluation\n3. Adult\n\nExclusion Criteria:\n\n1\\. Contra indication to MRI",{"count":142,"type":20},100,[23],"Prospective natural history pilot study to explore the link between muscle composition using an MRI-based Muscle Assessment Score (MAsS) and adverse outcomes in liver transplant candidates.",[146,113,27,147],"End Stage Liver DIsease","Cirrhosis","2025-08-12",{"date":150,"type":32},"2025-08-15",{"date":152,"type":32},"2022-11-02",{"date":154,"type":20},"2027-07-01",{"name":156,"class":39},"Mayo Clinic",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":48,"minAge":83,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":40},"100540693","dissecting-the-molecular-and-cellular-pathophysiology-of-sarcopenic-obesity-in-the-elderly-100540693","NCT06320158","Dissecting the Molecular and Cellular Pathophysiology of Sarcopenic Obesity in the Elderly","Inclusion Criteria:\n\npatients who are candidates for hip surgery\n\n* patients who are candidates for hip surgery\n* age ≥ 65 years\n* patients able to give consent\n\nhealthy subjects\n\n\\- healthy subjects from the geriatric cohort studied in 2016-2017 who at that time were: were overweight (25 ≤ BMI \\\u003C 30 kg\u002Fm2) or obese (BMI ≥ 30 kg\u002Fm2) but had not yet developed sarcopenia\n\nExclusion Criteria:\n\nAll partecipants\n\n* unavailability to participate in the study\n* inflammatory or neurological myopathies\n* acute heart failure\n* active cancer","99 Years",{"count":165,"type":20},1108,"Ageing is characterised by a change in body composition with a parallel decrease in muscle mass and an increase and central redistribution of fat. When drastically exacerbated, these two processes culminate in a condition known as sarcopenic obesity (SO). SO is characterised by the coexistence of obesity and sarcopenia (i.e. reduced muscle mass and function) and is a growing public health problem in the elderly. The health risks of obesity and sarcopenia act synergistically, maximising the risk of disability of OS. The molecular mechanisms underlying OS are largely unknown. Increased fat mass induces chronic systemic inflammation and alters the profiles of adipokines and hormones, promoting the development of sarcopenia. On the other hand, the reduction in muscle tissue (SM) typical of sarcopenia is characterised by an alteration in the metabolic properties of skeletal muscle with an increase in insulin resistance and a reduction in energy expenditure that favours the accumulation and dysfunction of adipose tissue (AT). The cellular alterations that would seem to underlie OS are: altered autophagy, cellular senescence, epigenetic and mitochondrial alterations and maladaptive activation of intra- and intercellular inflammatory circuits (e.g. cytokines, extracellular vesicles, dysfunctional circulating leukocytes). However, the interconnections between these mechanisms are still unclear. The impact of OS can be dramatic on the health and quality of life of those affected. Therefore, the identification of early biomarkers that can recognise overweight and obese individuals at risk of developing SO is of paramount importance. This would shed light on the heterogeneity of an otherwise homogeneous clinical condition, opening new horizons towards the conscious design of more personalised therapeutic strategies, allowing a more rational use of the limited resources available for the growing elderly population.\n\nThe study design designed to achieve this aim is a cross-sectional observational study with an additional multicentre procedure lasting two years.",[27],"2025-06-17",{"date":170,"type":32},"2025-06-18",{"date":172,"type":32},"2023-05-22",{"date":174,"type":20},"2025-12-31",{"name":176,"class":39},"IRCCS San Raffaele",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":48,"minAge":184,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":21,"phases":187,"briefSummary":188,"conditions":189,"keywords":194,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":40},"100595306","plant-vs-animal-based-protein-sources-as-an-anabolic-and-metabolic-protective-options-for-so-in-older-adults-100595306","NCT07030738","Plant vs Animal-based Protein Sources as an Anabolic and Metabolic-protective Options for SO in Older Adults","Plant (Legumes) vs Animal-based (Meat) Protein Sources as an Anabolic and Metabolic-protective Options for Sarcopenic Obesity in Older Adults- A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 55 years or older.\n* Diagnosed with obesity.\n* At risk for sarcopenia, based on at least one of the following: Low score on the validated SARC-F-calf questionnaire (as suggested in prior studies). More than one comorbidity associated with sarcopenic obesity (e.g., diabetes, osteoporosis, cardiovascular disease, etc.). Polypharmacy: taking 8 or more prescribed medications. Evidence of strength or functional impairment, assessed using validated measurements at the baseline visit.\n\nExclusion Criteria:\n\n* Recent use of steroid agents within the past 6 months (replacement therapy is allowed).\n* Uncorrected hypothyroidism: TSH \\> 6 mIU\u002FL.\n* Diagnosis of malignancy within the past 5 years, except for non-melanoma skin cancer.\n* Chronic kidney disease (CKD) at stage \\>1 (due to protein restriction needs).\n* Recent (≤6 months) or unstable cardiovascular condition, or NYHA Class III or higher congestive heart failure.\n* Currently performing resistance training.\n* Currently undergoing nutritional therapy, have recently changed diet (\\\u003C1 month), or are enrolled in active weight-loss programs or therapies (including lifestyle and\u002For pharmacotherapy). Note: Patients stable on GLP-1 agonists or other pharmacotherapy are eligible.\n* Vegetarians\u002Fvegans, or individuals with aversion or allergy to all legumes or all red meat products.\n* Habitual consumption of more than 3 servings\u002Fweek of either legumes or red meat.\n* Other medical, psychiatric conditions, or lab abnormalities that may pose a risk to participation.","55 Years",{"count":186,"type":20},180,[23],"This study is testing how different types of protein - from red meat, legumes (like lentils and beans), or a mix of both - affect muscle strength, body composition, and metabolic health in older adults with obesity who are also at risk for sarcopenia (loss of muscle mass and function). Participants will follow a personalized weight loss diet with one high-protein meal each day that includes either red meat, legumes, or both, along with a home-based strength training program. The study will last three months and will include health assessments such as blood tests, muscle and fat measurements, and physical function tests. The goal is to find out which type of protein source is most helpful for improving strength, reducing body fat, and supporting healthy aging.",[27,190,191,113,192,193],"Obesity and Obesity-related Medical Conditions","Obesity (Body Mass Index >30 kg\u002Fm2)","Muscle Loss","Aging",[195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212],"Plant-based diet","Red meat","Legumes","Protein intake","Anabolic diet","Resistance training","Muscle mass","Body composition","Older adults","Functional status","Sarcopenic obesity","Hypocaloric diet","Leucine","Physical function","Metabolic health","Aging population","Nutrition intervention","Randomized controlled trial","2025-06-12",{"date":215,"type":32},"2025-06-22",{"date":217,"type":20},"2025-09",{"date":219,"type":20},"2026-06",{"name":221,"class":222},"Tel-Aviv Sourasky Medical Center","OTHER_GOV",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":82,"sex":48,"minAge":230,"maxAge":163,"enrollmentInfo":231,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":233,"conditions":234,"keywords":237,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":40},"100544005","pilot-study-of-the-human-metagenome-in-metabolic-diseases-100544005","NCT06363253","Pilot Study of the Human Metagenome in Metabolic Diseases","Understanding the Role of the Human Metagenome in Obesity, Metabolic Diseases, Chronic Inflammation, Sarcopenia and Sarcopenic Obesity - a Pilot Study","Inclusion Criteria (obese cohort):\n\n* Obese (BMI\\>27.5kg\u002Fm2)\n\nInclusion Criteria (sarcopenic cohort):\n\n* Sarcopenic patients, defined as 1) low handgrip strength (\\\u003C26 for males; \\\u003C18kg for females), AND\u002FOR low gait speed (\\\u003C0.8m\u002Fs) AND low muscle mass (\\\u003C7.0kg\u002Fm2 for males; \\\u003C5.7kg\u002Fm2 for females)\n\nInclusion Criteria (control cohort):\n\n\\- Healthy subjects without sarcopenia, and not obese (BMI\\\u003C27.5kg\u002Fm2)\n\nExclusion Criteria:\n\n* No informed consent\n* Presence of intestinal stoma, hence inability to collect fecal samples","21 Years",{"count":232,"type":20},600,"This is a cohort study to understand the role of the human metagenome, and associated metabolites, in health and in various diseased states, in particular obesity as well as sarcopenia.\n\nRecruited participants will have their fecal, salivary, urine, serum, and in certain instances, mucosal samples taken, for metagenomic sequencing and metabolite testing.\n\nWe hope to uncover various differences and signatures in the metagenome and metabolome in various diseased states, with potential future therapeutic applications in personalised medicine.",[58,113,27,235,236],"Chronic Inflammation","Metabolic Syndrome",[58,113,238,239,240],"Metabolic syndrome","Metagenomics","Metabolomics","2025-05-12",{"date":243,"type":32},"2025-05-15",{"date":245,"type":32},"2023-08-14",{"date":247,"type":20},"2027-12-31",{"name":249,"class":39},"Sengkang General Hospital",{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":48,"minAge":83,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":21,"phases":259,"briefSummary":260,"conditions":261,"keywords":262,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":40},"100587856","dietary-modification-intervention-involving-family-support-famnutri-for-managing-sarcopenic-obesity-among-community-dwelling-older-adults-100587856","NCT06933823","Dietary Modification Intervention Involving Family Support (FamNUTRI) for Managing Sarcopenic Obesity Among Community-dwelling Older Adults","Dietary Modification Intervention Involving Family Support (FamNUTRI) for Managing Sarcopenic Obesity Among Community-dwelling Older Adults: a Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n1. older adults aged 65 years old or above who are living in the community and have not less than 4 shared meals with family weekly\n2. having a family member consent to offer support to the study participant\n3. diagnosed as having sarcopenic obesity using the diagnostic criteria of Asian Working Group for Sarcopenia (AWGS) for sarcopenia and definition from WHO for obesity for Asian, respectively: 3a)early-stage sarcopenia is defined by meeting one of the following criteria: low handgrip strength \\\u003C28 kg for men and \\\u003C18 kg for women, low appendicular skeletal muscle mass (ASM) \u002Fheight2 \\\u003C 7 kg\u002Fm2 for men and \\\u003C5.7 kg\u002Fm2 for women, or low physical performance with a Short Physical Performance Battery (SPPB) score of \\\u003C 9; 3b) Obesity is defined by meeting one of the following criteria: BMI ≥25 kg\u002Fm2, waist circumference ≥ 90 cm in men and ≥ 80 cm in women, or percentage of body fat \\>30%\n4. ability to read, write and understand Chinese without severe speaking, hearing and vision problems for intervention delivery.\n\nExclusion Criteria:\n\n1. having any existing disease or condition that affects digestion or food intake, such as severe heart diseases, renal diseases, depression or advanced stages of cancer\n2. having medications that impact dietary patterns, digestion, or metabolism\n3. following specific dietary pattern or restrictions, such as diabetic diets and renal diets\n4. having alcohol addiction defined by Alcohol Use Disorders Identification Test (AUDIT) scoring 8 or above since it may affect their ability and their determination to make changes in dietary modification\n5. having medical implants such as a pacemaker since the equipment to carry out bioelectric impedance analysis (Inbody S10) may cause malfunctioning of the implanted devices.",{"count":258,"type":20},72,[23],"The goal of this pilot RCT is to examine the feasibility and preliminary effects of a dietary modification intervention involving family support (FamNUTRI) on the management of sarcopenic obesity among older people living in the community. The main questions it aims to answer are:\n\n1. Is the intervention feasible and acceptable for community-dwelling older people with sarcopenic obesity?\n2. What are the preliminary effects of the intervention on managing sarcopenic obesity in this population?\n\nResearchers will compare the FamNUTRI group, the NUTRI group, and a passive control group to see if the dietary modification intervention with family support has additional benefits over the dietary modification intervention alone and no intervention.\n\nParticipants will:\n\nAttend 6 face-to-face one-hour bi-weekly sessions over 15 weeks Receive bi-weekly phone calls to foster adherence to the hypocaloric diet with high protein intake (For the FamNUTRI group) Invite a family member to attend the sessions together",[27],[27,263,264],"Dietary intervention","Pilot RCT","2025-04-17",{"date":267,"type":32},"2025-04-18",{"date":269,"type":20},"2025-04-15",{"date":271,"type":20},"2026-05",{"name":273,"class":39},"The Hong Kong Polytechnic University",{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":48,"minAge":83,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":21,"phases":285,"briefSummary":286,"conditions":287,"keywords":291,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":309},"100579643","feasibility-and-effectiveness-of-eccentric-exercise-in-sarcopenic-older-adults-with-heart-failure-a-pilot-study-100579643","NCT06826963","Feasibility and Effectiveness of Eccentric Exercise in Sarcopenic Older Adults with Heart Failure: a Pilot Study","The Role of Eccentric Exercise in the Older Sarcopenic Population with Heart Failure: a Feasibility and Efficacy Study Protocol","ECLYPSE-HF","Participants must meet all of the following criteria:\n\n* Age 65 to 85 years\n* Diagnosed with stable heart failure (HF), defined as:\n* Preserved left ventricular ejection fraction (≥50%) or\n* Reduced ejection fraction (≤40%)\n* Classified as New York Heart Association (NYHA) class 1, 2, or 3\n* Meet the diagnostic criteria for sarcopenia or sarcopenic obesity:\n* Sarcopenia: Impaired muscle strength with the Five-repetition chair stand test time \\>15 seconds (normal weight) or \\>17 seconds (patients with obesity)\n* Reduced muscle mass according to the European Working Group on Sarcopenia (EWGSOP) or Sarcopenic Obesity: Based on the European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO).\n* For EWGSOP:\n\nSarcopenia as Class I: Skeletal muscle mass index (kg\u002Fm²)\n\n* Males: ≤10.75 kg\u002Fm²\n* Females: ≤6.75 kg\u002Fm²\n* For EWGSOP:\n\nSarcopenia as Class II: Skeletal muscle mass index (kg\u002Fm²)\n\n* Males: ≤8.50 kg\u002Fm²\n* Females: ≤5.75 kg\u002Fm²\n* For ESPEN-EASO:\n\nObesity: waist circumference calculated in centimeters (cm)\n\n* Males: ≥102 cm\n* Females: ≥ 88 cm Sarcopenia as Class I: Skeletal muscle index as a percentage of body weight (%)\n* Males: 31.3-37%\n* Females: 22.1-27.6%\n\nSarcopenia as Class II:\n\n* Males: \\\u003C31.5%\n* Females: \\\u003C22.1%\n\nExclusion Criteria:\n\nParticipants will be excluded if they meet any of the following conditions:\n\n* Severe obstructive heart disease\n* Aortic valve stenosis\n* Severe arrhythmias identified during initial stress testing\n* Intracavitary thrombosis\n* Severe pulmonary hypertension (\\>70 mmHg)\n* History of venous thromboembolism within the previous three months\n* History of heart transplantation\n* Medical conditions that significantly limit functional capacity beyond the impact of HF","85 Years",{"count":284,"type":20},15,[23],"This study is designed to evaluate the safety, feasibility, and effectiveness of a 12-week eccentric exercise program for older adults with sarcopenia (muscle loss) or sarcopenic obesity and chronic heart failure (HF). The program aims to improve physical performance, muscle strength, and overall health without causing excessive strain on participants. Eccentric exercise has shown potential benefits for improving muscle function, and this study will help determine if it is a safe and effective option for individuals with heart failure and muscle loss.\n\nStudy Goals: The primary aim of this study is to test the feasibility and effectiveness of an eccentric exercise program for older adults with sarcopenia and CHF. The study will monitor physical performance, adherence to the program, and participants' ability to tolerate the exercise, as well as any impact on heart and muscle health.\n\nStudy Population: A screening visit will be scheduled to determine if individuals meet the criteria to participate in the study. During this visit, a detailed assessment will be made, and if eligible, participants will sign an informed consent form.\n\nThis study will assess whether a 12-week eccentric exercise program can help improve muscle strength, cardiovascular health, and overall physical performance in individuals with HF and sarcopenia. The program will involve exercising on an eccentric bike, which is designed to reduce strain on the heart while providing effective muscle strengthening benefits.\n\nThe study will use several physical performance tests to assess the impact of the exercise program, including:\n\n1. Short Physical Performance Battery (SPPB): Evaluates mobility and strength.\n2. 6-Minute Walk Test (6MWT): Measures cardiovascular fitness.\n3. Handgrip Strength and Leg Strength Tests: Assess upper and lower body muscle strength.\n4. Additionally, body composition will be evaluated using tools such as DXA scans and bioelectrical impedance analysis (BIA) to measure muscle mass, fat, and overall health status. The program's adherence and tolerance will be carefully monitored by measuring session completion, intensity, and participant feedback.\n\nPrimary Outcomes\n\nFeasibility Measures:\n\n1. Recruitment and Completion Rate: The ratio of participants recruited to those who successfully complete the study, including post-intervention assessments.\n2. Session Attendance: The number of training sessions attended out of the total planned sessions.\n3. Adherence to Training Volume: The number of prescribed exercises completed by participants compared to the total planned.\n4. Program Tolerance: Evaluated by comparing the Rate of Perceived Exertion (RPE) during sessions to the target RPE.\n\nTo be considered feasible, the study must meet these criteria: Recruitment \\>50%, Follow-up loss \\\u003C20%, Median attendance at training sessions \\>80%, Median adherence to prescribed volume \\>75%, Tolerance to RPE \\>70%.\n\nSecondary Outcomes\n\nEffectiveness Measures:\n\n1. SARC-F: A tool for identifying individuals at risk of sarcopenia, based on self-reported issues like weakness and difficulty walking.\n2. Mini Nutritional Assessment (MNA): Evaluates nutritional status to rule out malnutrition, which could affect training outcomes.\n3. Mini Mental State Examination (MMSE): Assesses cognitive function.\n4. Minnesota Living with Heart Failure Questionnaire: Evaluates how heart failure affects daily life.\n5. International Physical Activity Questionnaire (IPAQ): Measures physical activity levels at baseline.\n\nIn addition to the physical performance tests mentioned, the study will assess muscle mass and fat distribution using DXA scans and BIA, providing a comprehensive view of body composition. Finally, the feasibility of remotely monitoring patients' physical activity to determine the impact of the intervention on their daily lives, specifically in terms of mobility and autonomy is assessed. To this end, patients will be asked to wear a set of five sensors (two on the ankles, two on the wrists, and one on the waist) for at least four days. The Axivity AX6 sensors, chosen for their light weight and long battery life, will collect data used to monitor time spent moving, sitting, and lying down, as well as to assess the quality of the recorded movements.",[288,289,290,27],"Heart Failure with Preserved Ejection Fraction (HFPEF)","Heart Failure with Reduced Ejection Fraction","Sarcopenia in Elderly",[292,293,294,295,123,296,297,298,299],"eccentric exercise","older adults","heart failure","sarcopenia","muscle strength","muscle mass","exercise intervention","aging","2025-03-13",{"date":302,"type":32},"2025-03-14",{"date":304,"type":32},"2024-10-15",{"date":306,"type":20},"2025-09-30",{"name":308,"class":39},"Universita di Verona",2,{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":11,"sex":48,"minAge":83,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":21,"phases":319,"briefSummary":320,"conditions":321,"keywords":322,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":40},"100543789","effects-of-the-eatwellog-app-on-diet-management-for-older-adults-with-sarcopenic-obesity-100543789","NCT06360432","Effects of the EatWelLog App on Diet Management for Older Adults With Sarcopenic Obesity","Effects of the EatWelLog App on Enhancing Daily Diet Management for Community-dwelling Older Adults With Sarcopenic Obesity: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 65 or above, and living in the community;\n* Having SO according to the Asian Working Group for Sarcopenia (AWGS) and the World Health Organization (WHO)'s obesity criteria for Asians:\n\n  1. Early-stage sarcopenia indicated by fulfilment of one of the following criteria; handgrip strength \\\u003C28 kg (men) and \\\u003C18 kg (women); appendicular skeletal muscle mass (ASM)\u002F height2 \\\u003C7 kg\u002Fm2 (men) and \\\u003C5.7 kg\u002Fm2 (women), or SPPB score of \\\u003C9; Short Physical Performance Battery (SPPB) score of \\\u003C9,\n  2. Obesity indicated by BMI ≥25 kg\u002Fm2, waist circumference ≥90 cm (men) and ≥80 cm (women), or body fat \\>30%;\n* Own a smartphone with internet access; and\n* Proficiency in communicating, reading, and writing in Chinese, and without major hearing and vision impairments to ensure that comprehension of our instructions.\n\nExclusion Criteria:\n\n* Individuals with diseases impacting digestion or food consumption, including severe cardiac\u002F pulmonary\u002F renal diseases, diabetes, cancer, or autoimmune disorders;\n* Those on medications affecting eating habits, digestion, or metabolism, such as weight loss drugs;\n* Persons with alcohol use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), potentially hindering dietary behaviour changes;\n* Those with medical implants like pacemakers that could be disrupted by the bioelectric impedance analysis (BIA's) low-level electrical currents.",{"count":318,"type":20},40,[23],"Sarcopenic obesity, characterised by concurrent reduced muscle mass and excess body fat, affects 11% of older adults worldwide, rising to 23% in those over 75. Considering the negative synergistic impact on health, promoting muscle mass gains while reducing fat mass remains a significant challenge, necessitating urgent and effective intervention strategies for managing SO. Exercise and nutrition are the primary interventions recommended for SO.\n\nThis project aims to evaluate the effects of the EatWellLog App developed by the investigators' team for local older adults, in improving:\n\n* their sarcopenic obesity status, measured by all four diagnostic criteria, including grip strength, muscle mass, physical performance and body fat mass (primary outcome), and,\n* nutritional self-efficacy, nutritional status, dietary quality, health-related quality of life, and adherence to diet and exercise regimens (secondary outcomes), by enhancing the self-management abilities and longer-term adherence to daily diet management among participants in the M-health group using the App, compared to the control group.\n\nThe EatWellLog App, designed for older adults with SO, incorporating Klasnja and Pratt's five-strategy framework for mobile health (mHealth) applications development to facilitate health behavioural change. This App supports users with SO in managing daily diets that promote gradual weight loss and muscle mass preservation, adhering to the dietary regimen for this population.\n\nForty older adults with SO will be recruited from local community health centres and then randomized to either m-health or control groups. Both groups will receive an 8-week supervised programme separately. The programme consists of personalised dietary modification programme and group-based exercise training which have been tested and used in the investigators' pilot and General Research Fund (GRF) project. Additionally, only the m-health group will be instructed to use the App for daily diet self-management.\n\nParticipants will be assessed on a variety of outcomes immediately after the 8-week supervised programme (T1), which will be compared to the baseline (T0). To explore the possible long-term effects of the intervention, other measurements will be conducted at 3-(T2) and 6-(T3) months after the supervised programme, which will be compared with those conducted at T0.",[27],[27,323,324,325,326],"m-health","dietary intervention","exercise","behaviour change","2025-02-11",{"date":329,"type":32},"2025-02-13",{"date":331,"type":32},"2024-04-08",{"date":333,"type":20},"2025-10-31",{"name":273,"class":39},{"id":336,"slug":337,"hasResults":11,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":11,"sex":48,"minAge":343,"maxAge":344,"enrollmentInfo":345,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":347,"conditions":348,"keywords":350,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":40},"100579300","prevalence-of-sarcopenic-obesity-in-copd-100579300","NCT06822504","Prevalence of Sarcopenic Obesity in COPD","ESPEN-EASO Sarcopenic Obesity (OS) Diagnostic Criteria Application in a COPD Cohort and OS Correlation to Diaphragmatic Thickness and Mobility for Determination of Tailored Pulmonary Rehabilitation Program: an Observational Study","OS-BPCO","Inclusion Criteria:\n\n* Patients aged \\> 40 years of either sex;\n* BMI \\>18.5\n* COPD diagnosis according to the GOLD \\[2021 Global initiative for chronic obstructive lung disease\\] classification in the stable stage;\n* Signing of informed consent after receiving all information about the study.\n\nExclusion Criteria:\n\n* COPD not stabilized at the time of enrollment;\n* BMI \\\u003C 18.5\n* presence of tracheostomy\n* uncontrolled hypertension (systolic blood pressure \\> 160 mmHg, diastolic \\> 100 mmHg);\n* hypotension (systolic blood pressure \\\u003C100 mm Hg);\n* Significant comorbidities that limit exercise tolerance;\n* intercurrent infectious diseases, including HIV diagnosis;\n* Patients diagnosed with malignancy in progress or in remission for less than 5 years;\n* patients diagnosed with severe neurological, rheumatologic, or musculoskeletal diseases;\n* patients with a history of thoracic surgery;\n* presence of severe aortic stenosis, uncontrolled atrial\u002Fventricular arrhythmia, recent cardiac ischemic event;\n* cognitive impairment conditions that prevent full understanding of the study protocol (mental retardation, dementia, etc.) and\u002For adequate test performance compliance;\n* failure to sign informed consent;\n* any other serious medical condition that may interfere with data interpretation and safety or that may make the respiratory rehabilitation course difficult, limited, or uncomfortable.","40 Years","100 Years",{"count":346,"type":20},236,"The goal of this observational study is to the purpose is to apply of ESPEN\u002FEASO criteria for the diagnosis of sarcopenic obesity and calculation of OS prevalence in a sample of COPD patients.\n\nIn addition, this study want to evaluate the impact of sarcopenic obesity on the respiratory function of COPD patients and the degree of severity of respiratory disease, assessed by spirometric examination; diaphragm thickness and excursion, by ultrasonographic study; performance, assessed by six-minute walk test (6-MWT); quality of life and degree of dyspnea (mMRC, Barthel dyspnea, S. George Respiratory Questionnaire); compliance and outcomes at the end of the respiratory rehabilitation course. Comparison with normal-weight patients with and without sarcopenia will help to better understand the clinical impact of sarcopenic obesity in this category of patients.",[27,349],"COPD",[123,349,351],"diaphragmatic ultrasound","2025-02-06",{"date":354,"type":32},"2025-02-12",{"date":356,"type":32},"2024-06-01",{"date":358,"type":20},"2025-06-30",{"name":360,"class":39},"IRCCS San Raffaele Roma",{"id":362,"slug":363,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":48,"minAge":49,"maxAge":4,"enrollmentInfo":368,"targetDuration":370,"studyType":86,"phases":4,"briefSummary":371,"conditions":372,"keywords":373,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":40},"100578798","validation-of-an-algorithm-for-the-diagnosis-of-sarcopenic-obesity-100578798","NCT06815978","Validation of an Algorithm for the Diagnosis of Sarcopenic Obesity","Validation of ESPEN-EASO Algorithm for the Diagnosis of Sarcopenic Obesity (SO)","Inclusion Criteria:\n\n* BMI equal more than 30\n* Caucasians\n\nExclusion Criteria:\n\n* any disease or medication that can significantly affect body composition (eg.malignant diseases in the last 5 years, autoimmune diseases, neurological diseases, syndromic obesity),\n* level of physical activity more than 3 METS\n* alcohol intake more than 140g\u002Fwk for M and 70g\u002Fwk for F\n* participation in a weight-reducing program (last 3 months),\n* impossibility to perform DXA exam\n* pregnancy and breast-feeding.",{"count":369,"type":20},150,"24 Months","The proposed research project aims to investigate sarcopenic obesity (SO), a condition characterized by the combination of high body fat and low skeletal muscle mass, with a focus on muscle function. SO has been defined according to the ESPEN-EASO algorithm, and this study aims to evaluate its validity, exploring associations with circulating biomarkers and functional outcomes. By enrolling 75 subjects with SO and a control sample of 75 subjects with non-sarcopenic obesity, the primary objective of this study is to examine the consistency of the proposed diagnostic criteria with respect to circulating biomarkers and functional outcomes. Secondary objectives include the assessment of additional variables and the detailed profiling of SO subjects through questionnaires and multidimensional tests. The ethical aspect of the present study will be guaranteed through written informed consent and protection of privacy, respecting international regulatory standards. The investigators believe that this work provides significant contributions to the understanding of sarcopenic obesity and to the validation of diagnostic criteria, with possible implications for public health. The investigators are available for further clarifications and approvals required by the Ethics Committee.",[27],[205,374,375,376,377],"obesity","nutrition","gut microbiome","diagnostic ciriteria","2025-02-04",{"date":380,"type":32},"2025-02-10",{"date":382,"type":32},"2024-05-24",{"date":384,"type":20},"2027-03-01",{"name":386,"class":39},"Elisa Giannetta",{"id":388,"slug":389,"hasResults":11,"nctId":390,"briefTitle":391,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":11,"sex":48,"minAge":16,"maxAge":4,"enrollmentInfo":393,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":395,"conditions":396,"keywords":399,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":4},"100570278","comparative-analysis-of-sarcopenia-in-rehabilitation-outcomes-following-femoral-neck-fracture-a-study-in-normal-weight-and-obese-study-cohort-100570278","NCT06705166","Comparative Analysis of Sarcopenia in Rehabilitation Outcomes Following Femoral Neck Fracture: a Study in Normal Weight and Obese Study Cohort","Inclusion Criteria:\n\n* Age between 60-85\n* Suffered a femoral neck fracture in the last year.\n* Subject willing and able to read, understand and sign an informed consent.\n\nExclusion Criteria:\n\n* Inability to comply with the study protocol or understand and sign an informed consent\n* Diagnosis of a psychiatric disorder prior to the recent femoral neck.\n* Active malignancy\n* History of other neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Lewy Body Dementia (LBD), Frontotemporal dementia (FTD), Multiple sclerosis (MS), Amyotrophic lateral sclerosis (ALS), Creutzfeld Jacob disease (CJD), Multisystem atrophy (MSA), Pseudobulbar palsy (PSP), Corticobasal degeneration (CBD), Wernicke Korsakoff syndrome\n* Chronic Inflammatory Disorders:(e.g., rheumatoid arthritis, systemic lupus erythematosus).\n* Endocrine Disorders: Individuals with endocrine disorders affecting muscle metabolism (e.g., Cushing's syndrome, hyperthyroidism)\n* Recent Major Surgeries: Participants who had undergone major surgeries other than femoral neck fracture within the last six months",{"count":394,"type":20},300,"Impact of Obesity on Sarcopenia Prevalence and Severity in Elderly Adults Recovering from Femoral Neck Fractures: A Prospective Study\n\nIntroduction Age-related muscle loss, or sarcopenia, which includes reductions in both muscle mass and function, is increasingly recognized as a critical health issue in the elderly. Sarcopenia is associated with frailty, disability, and increased mortality. With its rising prevalence, obesity further complicates aging, leading to a condition termed \"sarcopenic obesity\" (SO), where sarcopenia coexists with obesity. This combination amplifies risks for physical disability, falls, and fractures in older adults. Although sarcopenia and obesity individually contribute to adverse health outcomes, their combined impact on recovery from hip fractures, particularly femoral neck fractures, is under-researched. Hip fractures severely impact the elderly, with over 40% failing to regain pre-fracture functionality and a mortality rate above 35% within three years post-fracture.\n\nThis study aims to assess the impact of obesity on sarcopenia prevalence and severity in older adults recovering from femoral neck fractures, addressing an essential gap in understanding SO's role in post-fracture rehabilitation outcomes.\n\nObjectives\n\n* To evaluate the prevalence and severity of sarcopenia among normal-weight versus obese elderly adults post-femoral neck fracture.\n* To investigate the association between sarcopenic obesity and functional recovery.\n* To determine whether obesity modifies sarcopenia's impact on rehabilitation outcomes.\n\nRisk-Benefit Statement The study entails minimal risk, as all procedures are non-invasive and consistent with routine rehabilitation practices. The potential benefits include enhanced understanding of sarcopenia's effect on hip fracture recovery, which may inform improved rehabilitation practices. Comprehensive health assessments may also benefit participants' post-fracture care.\n\nStudy Design Overview This prospective observational study includes hospitalized elderly patients undergoing rehabilitation post-femoral neck fracture. After obtaining informed consent, participants will complete an initial assessment, including demographic information, medical history, cognitive status, and anthropometric measurements. Blood samples will be collected for biochemical markers.\n\nStratification and Assessment:\n\nPatients will be categorized into normal-weight and obese groups. Comprehensive assessments, including cognitive function, mobility, frailty, muscle strength, and nutritional status, will establish a baseline for studying sarcopenia and obesity's impact on rehabilitation outcomes.\n\nPopulation and Criteria:\n\nSample Size: Up to 300 participants\n\nInclusion Criteria:\n\n* Age 60-85\n* Recent femoral neck fracture (within the past year)\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Inability to comply with study requirements\n* History of neurodegenerative or psychiatric conditions, recent major surgeries (excluding femoral neck fracture), or conditions affecting muscle metabolism\n\nProcedures:\n\nBaseline Evaluation:\n\n* Cognitive Function: Mini-Mental State Examination (MMSE)\n* Anthropometric Measurements: BMI from height and weight\n* Functional Independence (FIM): Level of independence in daily activities\n* Mobility (Up \\& Go Test): Indicator of balance and mobility\n* Frailty and Muscle Strength: Handgrip strength, SARC-F questionnaire, Muscle Strength and Reflex Assessment (MSRA)\n* Nutritional Status: Mini Nutritional Assessment (MNA)\n* Laboratory Tests: CRP, calcium, vitamin D, CBC\n\nPost-Rehabilitation Evaluation:\n\nAfter rehabilitation, participants will repeat baseline assessments to determine changes in sarcopenia severity and functional status.\n\nUnscheduled Visits:\n\nParticipants may request evaluations outside the scheduled timeline, documented by the investigator as necessary.\n\nStatistical Analysis\n\n* Descriptive Analysis: Mean and standard deviations for continuous data, frequencies for categorical data.\n* Comparative Analysis: Independent t-tests to compare normal-weight and obese groups, dependent t-tests for within-group changes.\n* Univariate Analysis: Chi-square or Fisher's exact tests with a significance level of P \\\u003C 0.05.\n\nEthics and Confidentiality This study will adhere to the Declaration of Helsinki, ICH-GCP guidelines, and applicable regulations. Informed consent will be obtained from all participants, and confidentiality measures will protect patient privacy, with data limited to authorized personnel and anonymized in reports.\n\nInstitutional Review Board (IRB) Approval\n\nIRB approval will be obtained from the Israeli Ministry of Health, following ICH-GCP guidelines. The IRB will oversee the study protocol, consent forms, and all participant materials.\n\nData Storage and Study Termination\n\nData will be securely stored, with",[290,27,397,398],"Frailty","Femoral Fractures",[293,295,374,400,401],"rehabilitation","femoral fractures","2024-11-21",{"date":404,"type":32},"2024-11-26",{"date":406,"type":20},"2024-11-15",{"date":408,"type":20},"2026-01-01",{"name":410,"class":222},"Shmuel Harofeh Hospital, Geriatric Medical Center",{"id":412,"slug":413,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":11,"sex":48,"minAge":50,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":21,"phases":420,"briefSummary":421,"conditions":422,"keywords":423,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":40},"100567719","feasibility-of-at-home-chair-based-resistance-band-training-to-improve-balance-strength-and-bone-density-in-older-adults-100567719","NCT06671847","Feasibility of At-Home Chair-Based Resistance Band Training to Improve Balance, Strength, and Bone Density in Older Adults","Feasibility of 24-Weeks of At-Home Chair-Based Resistance Band Training to Improve Balance, Strength, and Bone Density in Older Adults (ChaREx Study)","ChaREx","Inclusion Criteria:\n\n* English-speaking\n* receive care at the UT Physician Center for Healthy Aging\n\nExclusion Criteria:\n\n* inability to provide informed consent on their own\n* presence of obvious signs of cognitive decline\n* a diagnosis of dementia and inability to come to the clinic for the scheduled study visits.",{"count":318,"type":20},[23],"The purpose of this study is to determine the feasibility of implementing a 24-week at-home chair-based resistance band training intervention, to determine effectiveness of a the a 24-week at-home chair-based resistance band training intervention in improving body composition and to determine the effectiveness of a 24-week at-home chair-based resistance band training intervention in improving physical performance in adults 50 years and older, receiving care at the UT Physicians Center for Healthy Aging.",[27],[424],"chair-based resistance band exercise","2024-11-01",{"date":427,"type":32},"2024-11-04",{"date":429,"type":20},"2025-01-01",{"date":431,"type":20},"2026-09-30",{"name":433,"class":39},"The University of Texas Health Science Center, Houston",{"id":435,"slug":436,"hasResults":11,"nctId":437,"briefTitle":438,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":11,"sex":48,"minAge":50,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":442,"conditions":443,"keywords":448,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":40},"100526576","the-effect-of-sarcopenic-obesity-on-sleep-in-individuals-with-obesity-hypoventilation-syndrome-100526576","NCT06136533","The Effect of Sarcopenic Obesity on Sleep in Individuals With Obesity Hypoventilation Syndrome","Inclusion Criteria:\n\n* \\>50 years old\n* 30\\\u003C BMI\\\u003C 45 kg\u002Fm2\n* Patients who have undergone polysomnography evaluation within the last 6 months\n\nExclusion Criteria:\n\n* Patient who have immobilized for more than 15 days in the last 6 months\n* Patient who have used corticosteroids in the last 6 months\n* Patient who have been significant weight loss in the last 6 months\n* Patient who have been significant serious comorbidities (cognitive impairments, neuromuscular diseases, unstable heart problems, uncontrolled respiratory problems, unresolved thyroid problems, etc.) that may affect participation in the study",{"count":441,"type":20},64,"Obesity Hypoventilation Syndrome(OHS) is characterized by daytime hypercapnia and sleep-disordered breathing without other causes of hypoventilation in individuals with a body mass index above 30 kg\u002Fm2. It is stated that obesity is at the basis of the metabolic changes seen in individuals diagnosed with OHS. Also sedentary lifestyle habits, which are common in obese individuals, cause the risk of sarcopenia due to loss of muscle strength and mass, accumulation of adipose tissue in the body, and decreased exercise capacity. Reduced exercise capacity due to obesity has been shown in the literature to strongly interact with mortality risk. As a result of obesity and all this negative picture, impaired emotional state and decreased quality of life are observed in individuals. Simultaneously, sleep parameters are also negatively affected. In particular, increased adipose tissue leads to loss of muscle mass and strength, increased risk of sarcopenia and sleep-related problems. The association of obesity and sarcopenia is referred to as 'sarcopenic obesity'. Sarcopenic obesity is defined as the coexistence of sarcopenia and obesity. The concept of sarcopenic obesity has recently taken its place in the literature. In particular, there are very few studies on its relationship with sleep parameters. However, while obesity is the basis of OHS, there are no studies on the presence and effects of sarcopenic obesity in this patient group. Based on this point, we aim to investigate the effects of sarcopenic obesity on sleep parameters, exercise capacity and quality of life in individuals with OHS.",[444,58,445,446,447,113,27],"Obesity Hypoventilation Syndrome (OHS)","Hypoventilation","Respiration Disorders","Sleep Disorder; Breathing-Related",[444,58,113,27,449,450,447,451],"Sleep","Quality of Sleep","Polysomnography","2024-08-11",{"date":454,"type":32},"2024-08-13",{"date":456,"type":20},"2025-07-10",{"date":458,"type":20},"2025-10-01",{"name":460,"class":39},"Istanbul University"]